Key Takeaways
- • ValueAct Capital sold nearly all of its remaining 11.8 million Adobe shares in March 2016 for more than $1 billion, exiting a decade-long position that generated approximately 300% returns on an initial $200 million investment made in 2011.
- • Valeant Pharmaceuticals stock collapsed 51% in a single day in mid-March 2016 and has declined 90% from its August 2015 highs, overshadowing ValueAct's successful Adobe exit and dominating market perception of the hedge fund's track record.
- • ValueAct, which managed approximately $3.5 billion in assets at the time, has maintained continuous board representation at Valeant since 2007, currently holding two seats, and played a central role in recruiting and supporting CEO Michael Pearson, who departed following the stock collapse.
- • ValueAct's initial $200 million Valeant investment in 2006 exemplifies the firm's activist investment approach, though the company's subsequent strategy—emphasizing acquisitions over R&D, aggressive drug price increases, and cost-cutting measures—has been widely criticized as a public policy disaster within the healthcare sector.
- • The timing of ValueAct's Adobe exit coinciding with Valeant's March 2016 crisis reveals the contrast between the firm's successful long-term partnerships with quality management (Adobe, Gartner, Microsoft) and its controversial involvement in value extraction at Valeant.
Summary
ValueAct Capital Management's March 2016 exit from Adobe Systems represented a landmark transaction that received minimal Wall Street attention due to simultaneous turmoil at Valeant Pharmaceuticals. Jeffrey Ubben's hedge fund liquidated nearly all of its remaining 11.8 million Adobe shares for more than $1 billion, concluding a five-year investment cycle that began in 2011 when ValueAct acquired approximately 31.3 million shares representing a 6.3% stake. The position generated returns of roughly 300% as Adobe navigated a multi-year business transformation, demonstrating ValueAct's core investment methodology: accumulating significant stakes, placing board representatives, and partnering with management to drive long-term value creation.
However, the Adobe success narrative was entirely eclipsed by Valeant's catastrophic March 2016 collapse. Valeant's stock plunged 51% in a single trading day, and CEO Michael Pearson—personally selected and supported by ValueAct years earlier—departed his position. By June 2016, Valeant's stock had declined 90% from its August 2015 peak, making it the defining investment outcome associated with ValueAct rather than its successful Adobe, Gartner, and Microsoft positions.
ValueAct's decade-long involvement with Valeant began in 2006 when the then-relatively-obscure hedge fund, managing $3.5 billion in assets, deployed $200 million into the pharmaceutical company. Since 2007, ValueAct maintained nearly uninterrupted board representation, currently occupying two seats. Beyond board participation, ValueAct shaped Valeant's strategic direction, endorsing an acquisition-focused model that prioritized buying existing drug portfolios over internal research and development investments. This strategy—coupled with aggressive drug price increases and controversial tactics to maximize patient and insurer payments—became widely viewed as damaging to the broader pharmaceutical industry and public policy.
The contrast between ValueAct's Adobe and Valeant legacies underscores a fundamental tension in activist investing: the difference between constructive partnerships that enhance operational quality and value-extraction strategies that prioritize financial engineering over sustainable business building. While Ubben's firm successfully guided Adobe through transformative change, its central role in architecting Valeant's business model—which emphasized cost-cutting, workforce reductions, and aggressive pricing—contributed to a public policy disaster that ultimately destroyed shareholder value and drew sustained criticism from healthcare industry observers.
However, the Adobe success narrative was entirely eclipsed by Valeant's catastrophic March 2016 collapse. Valeant's stock plunged 51% in a single trading day, and CEO Michael Pearson—personally selected and supported by ValueAct years earlier—departed his position. By June 2016, Valeant's stock had declined 90% from its August 2015 peak, making it the defining investment outcome associated with ValueAct rather than its successful Adobe, Gartner, and Microsoft positions.
ValueAct's decade-long involvement with Valeant began in 2006 when the then-relatively-obscure hedge fund, managing $3.5 billion in assets, deployed $200 million into the pharmaceutical company. Since 2007, ValueAct maintained nearly uninterrupted board representation, currently occupying two seats. Beyond board participation, ValueAct shaped Valeant's strategic direction, endorsing an acquisition-focused model that prioritized buying existing drug portfolios over internal research and development investments. This strategy—coupled with aggressive drug price increases and controversial tactics to maximize patient and insurer payments—became widely viewed as damaging to the broader pharmaceutical industry and public policy.
The contrast between ValueAct's Adobe and Valeant legacies underscores a fundamental tension in activist investing: the difference between constructive partnerships that enhance operational quality and value-extraction strategies that prioritize financial engineering over sustainable business building. While Ubben's firm successfully guided Adobe through transformative change, its central role in architecting Valeant's business model—which emphasized cost-cutting, workforce reductions, and aggressive pricing—contributed to a public policy disaster that ultimately destroyed shareholder value and drew sustained criticism from healthcare industry observers.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.